Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research. That's according to company-sponsored studies reported …
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a digital subscriber with an active subscription, then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
